Intensive Dose-Dense Compared With Conventionally Scheduled Preoperative Chemotherapy for High-Risk Primary Breast CancerMichael Untch, Gottfried E. Konecny|Journal of Clinical Oncology|2009Cited by 151
Phase III MIRASOL (GOG 3045/ENGOT-ov55) study: Initial report of mirvetuximab soravtansine vs. investigator's choice of chemotherapy in platinum-resistant, advanced high-grade epithelial ovarian, primary peritoneal, or fallopian tube cancers with high folate receptor-alpha expression.Kathleen N. Moore, Toon Van Gorp, Gottfried E. Konecny et al.|Journal of Clinical Oncology|2023Cited by 53